CUE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cue Biopharma Inc (CUE) is not a strong buy for a beginner investor with a long-term focus at this moment. Despite positive news catalysts and a strategic partnership, the recent significant price drop, lack of strong trading signals, and mixed financial performance suggest caution. Holding the stock to monitor further developments is advisable.
The MACD is positive and expanding, indicating a bullish momentum. However, the RSI is neutral at 69.712, and moving averages are converging, showing no clear trend. Key support is at 0.457, and resistance is at 0.707. The stock is currently trading below its previous close, with a significant regular market decline of -15.06%.
Cue Biopharma announced a strategic collaboration with Boehringer Ingelheim to develop CUE-501 for autoimmune diseases, receiving a $12 million upfront payment and potential milestone payments of up to $345 million. Retail sentiment remains extremely bullish.
The stock has declined by 28% over the past year, and recent market activity shows a significant regular market drop of -15.06%. There is no recent congress trading data or strong hedge fund/insider activity to support a bullish case.
In 2025/Q4, revenue increased significantly by 1292.26% YoY to $21.94 million. However, net income dropped by -116.69% YoY to $1.59 million, and EPS declined by -107.69% YoY to 0.01. Gross margin remained steady at 100%.
No recent analyst rating or price target changes are available for Cue Biopharma Inc.
